Update on Antiplatelet Therapies for Stroke

Gordon Kelley MD, FAAN
AdventHealth Shawnee Mission
Talk Outline

• Brief review of coagulation and thrombosis
• Platelet physiology
• Anti-platelet agents
  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Other agents
  • Dual anti platelet strategies
• Prevention strategies
  • Primary prevention
  • Acute stroke intervention
  • Secondary prevention
• Future strategies
Haemostasis overview:

- BV Injury
- Neural
- Contact/Tissue Factor

Blood Vessel Constriction

Platelet Aggregation

Coagulation Cascade

- Primary hemostatic plug
- Reduced Blood flow
- Platelet Activation
- Fibrin formation

Stable Hemostatic Plug
Clotting Cascade

Contact activation (intrinsic) pathway

Tissue factor (extrinsic) pathway

Damaged surface

XII
XIIa
XIa
IX
IXa
VIIIa
VIII
IX
X
Prothrombin (II)

Tissue factor

Trauma

TFPI

Antithrombin

Common pathway

Fibrinogen (I)

Fibrin (Ia)

Cross-linked fibrin clot

Protein C + Thrombomodulin

Protein S

Active Protein C

Xa

Thrombin (IIa)

Va

XIIIa

XIII
Platelet Activation

**Resting platelet**
- α-granules
- P-selectin
- CD41/CD61
- GPIba
- TBXA2R
- β3 integrin

**Activated platelet**
- ADP
- P2Y12
- PAR1/4
- Thrombin
- GPIIbα
- α-granules
- TXA2
- Fibrinogen
- Von Willebrand Factor, Mac-1, P-selectin
- PF4, TGF-β, PDGF, VEGF, S1P, 5-HT, IL-1β, CCL5, CCL3...
Blood flow

Disturbed blood flow

ADP, TXA₂

Inhibition of platelet activation

PolyP

Factor XII

Fibrin

PGI₂, NO

Endothelial cell

Collagen

vWF

TF triggers the generation of thrombin

Formation of procoagulant platelets and coated platelets

Amplification of thrombin generation

Activation of the intrinsic coagulation pathway

Expansion of the fibrin network

Resting platelet

Loosely aggregating platelet

Aggregating platelet

Procoagulant platelet

Coated platelet
SEQUENCES IN PROGRESSION OF ATHEROSCLEROSIS

- Initial lesion
- Fatty streak
- Intermediate lesion
- Atheroma
- Fibroatheroma
- Complicated lesion

Clinically silent

Clinically silent of overt

ENDOTHELIAL DYSFUNCTION
White Clot vs Red Clot
Thrombus Evolution with Time

A: activated platelet fibrin mesh red blood cells
B: platelet contraction polyhedrocytes
C: infiltrated neutrophils

red blood cell polyhedrocytes unactivated platelets activated platelets platelets (contracted) neutrophil NETs fibrin
<table>
<thead>
<tr>
<th>Condition</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrin and plasma protein dominant clot analogue</td>
<td><img src="image1.png" alt="Image" /></td>
</tr>
<tr>
<td>Fresh thrombus encapsulating mature fibrin core</td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>Composite clot with calcific inclusion</td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td>Layered clot with mature fibrin base and fresh erythrocyte deposition</td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>Young erythrocyte-rich atrial fibrillation clot analogue</td>
<td><img src="image5.png" alt="Image" /></td>
</tr>
<tr>
<td>Fresh, erythrocyte-rich carotid clot analogue</td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td>Highly organized fibrin-rich atrial fibrillation clot analogue</td>
<td><img src="image7.png" alt="Image" /></td>
</tr>
<tr>
<td>Partially matured left atrial appendage clot analogue</td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
<tr>
<td>Shear-induced fibrin-rich prosthetic valve clot analogue</td>
<td><img src="image9.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Aspirin**
Binds cyclooxygenase 1 and inhibits thromboxane A2 (TXA2) synthesis.

**Thrombin**

**Vorapaxor**
Binds protease-activated receptor (PAR)-1 and inhibits thrombin-induced platelet activation.

**Clopidogrel**
Prasugrel
Ticagrelor
Cangrelor

**Binds to P2Y12 receptor and inhibits adenosine diphosphate (ADP) induced platelet activation**

**Abciximab**
Eptifibatide
Tirofiban

**Binds to glycoprotein IIb/IIia (GpIIb/IIia) receptor and inhibits aggregation**

**Activated Platelet**

**TXA2**

**Thromboxane receptor**

**PAR-1**
Aspirin

- Irreversibly blocks cyclo-oxygenase (COX) activity of prostaglandin (PG)H synthase 1 (COX-1) and 2 (COX-2)
- Induces permanent defect of thromboxane-A$_2$-dependent platelet function that includes platelet aggregation and causes vasoconstriction
- Peak half life is 15-30 minutes
- Loading dose: 160-325 mg; maintenance dose: 81 mg
- Risk of GI bleeding is dose dependent.
- Enteric coating slows half life to 3-4 hours & DOES NOT protect against GI bleeding
- Overall vascular RR by 19% but risk of hemorrhagic stroke RR 1.9 and GI bleeding RR 2.7)

Antithrombotic Trialist’s Collaboration Lancet 2009

- Other NSAIDs competitively bind to COX receptors but do not induce irreversible inhibition
  - NSAIDs should be taken 30 minutes after or 8 hours before ASA
- Possible other beneficial effects on endothelial cells and neutrophils
- Cost: ($6 /year)
Aspirin Treatment Failure

• Nonadherence
• NSAID interactions
• Enteric coating may cause decreased drug absorption (Grosser, T et al Circulation 2013;127:377-385)
• Possible role of dosage and patient weight
  • Pooled analysis for all vascular events (not stroke specific) suggested 75-100 mg for <70 kg and higher doses for >70 kg
• Tachyphylaxis or genetic polymorphisms
• No difference in comparative effectiveness of 81mg vs 325 mg in 15K patients followed 2 years in secondary prevention (Jones et al N Engl J Med 2021;384:1981-90)
• High platelet turnover (eg atherosclerosis)
• Equivocal/low level evidence of possible benefit in switching to alternative antiplatelet agent
Clopidogrel

- One of the thienopyridines (with ticlopidine, prasugrel, & ticagrelor) which block the P2Y12 receptor leading to irreversible indirect platelet inhibition
- No data on treatment alone in acute stroke
- Secondary prevention: relative risk reduction compared to ASA of 7.3%
- Slightly lower risk of bleeding than ASA GI bleeding (.52% vs 0.72%) and (intracranial hemorrhage (0.33% vs 0.47%)
- Prodrug: requires 2-step activation by 2 cytochrome P-450 enzymes
  - Theoretical concerns about drug interactions (esp PPIs) & genetic variations (65% Asians and 35% western populations have loss of function alleles)
  - Usefulness of genotyping is controversial; possibly of use in recurrent stroke on clopidogrel

- Cost: 15 cents/tablet or $54.75 year
Ticagrelor

• Not a prodrug
• Binds reversibly to P2Y12 receptor
• $T_{1/2}$ of 7-8 hours (must be dosed twice daily)
• More effective than clopidogrel in preventing MI, stroke or vascular death in ACS (PLATO trial)
• Increased efficacy when used with ASA
• Increased risk of bleeding

• Cost: ($403.56/mo with GoodRX; $4,843/year)
Other Antiplatelet Agents

• Dipyridamole & Cilostazol
• Block phosphodiesterase, resulting in decreased reputable of adenosine and elevated levels of cAMP and gAMP
• Prolong platelet survival, reduce inflammation, scavenge free radicals and produce vasodilation
• Dipyridamole used clinically chiefly in combination with aspirin
• Cilostazol marketed in US to treat peripheral vascular disease
  • Japanese trials have suggested benefit following carotid endarterectomy and in secondary stroke prevention
  • trial of cilostazol + either ASA or Clopidogrel for non lacunar stroke in progress
• Vasodilation associated with frequent complaint of headache as main s/e
Dual Antiplatelet Strategies

ASA + Dipyridamole
• No trials have tested its role in acute ischemic stroke
• Risk of recurrent stroke .82 compared with ASA alone
• Disadvantages: twice daily dosing; headache; high noncompliance rate

ASA + Clopidogrel
• Increased risk of bleeding (.9% DAPT vs 0.4% ASA alone)
• Short term benefit: current cut point is 21 days

ASA + Ticagrelor
• .79 hazard ratio of recurrent stroke vs ASA alone but 4 times as much bleeding and no overall significant effect of disability or death
Benefit vs Risk
Risk vs Benefit

• Bleeding risk is increased in:
  • Age over 65
  • BMI< 18.5
  • Diabetes
  • Prior bleeding
  • Taking oral anticoagulants

• Risk of bleeding can likely be decreased by adding a PPI
• Risk of ICH can likely be reduced with aggressive BP control
AntiPlatelet Therapy: Clinical Situations

• Primary Prevention
• Acute stroke management
• Secondary Prevention
  • Early
  • Late
Case 1

60 year old male treated for hypertension and diabetes with no history of vascular events or bleeding problems asks you if he should start taking aspirin to prevent a stroke or heart attack. You reply:

A. He should start 81 mg ASA a day
B. He should start 325 mg ASA a day
C. He should take enteric coated 325 mg ASA
D. His risk of bleeding outweighs his risk of benefit
United States Preventative Services Task Force Recommendations 2016

**Primary Prevention**

**Recommendation Summary**

<table>
<thead>
<tr>
<th>Population</th>
<th>Recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults aged 50 to 59 years with a 10% or greater 10-year CVD risk</td>
<td>The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.</td>
<td>B</td>
</tr>
<tr>
<td>Adults aged 60 to 69 years with a 10% or greater 10-year CVD risk</td>
<td>The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin.</td>
<td>C</td>
</tr>
<tr>
<td>Adults younger than 50 years</td>
<td>The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults younger than 50 years.</td>
<td>I</td>
</tr>
<tr>
<td>Adults aged 70 years or older</td>
<td>The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults aged 70 years or older.</td>
<td>I</td>
</tr>
</tbody>
</table>

**United States Preventative Services Task Force Recommendations 2016**

**USPSTF Task Force summary 2016 doi:.org/10.7326/M16-0577**

**2021 Draft Recommendations**
Case 2

A 55 year old woman with BMI 33 and history of diabetes, hypertension and smoking is seen in the ER 6 hours after developing mild right hemiparesis and dysarthria (NIHSS 3).

She should be given:

A.  ASA 81 mg now and daily
B.  ASA 162 mg now and 81 mg daily
C.  ASA 325 mg now and 81 mg daily
D.  ASA 325 mg now and daily
Preventing early recurrent stroke
- Risk of recurrent stroke about 10% w/i 1st week Aspirin started w/i 48 hr of stroke may have marginal benefit
- Cilostazole & dipyridamole appear to be less effective
- Ticagrelor + ASA vs ASA (THALES study) showed decreased risk of stroke (hazard ratio 0.79) but 4 times increased risk of serious bleeding (28 vs 7)
- Ongoing CHANCE-2 trial is comparing ASA+clopidogrel vs ASA+ticagrelor in acute stroke/TIA

Halting neurological worsening (stroke in evolution)
- More common in vertebrobasilar infarcts; esp. multilobar
- 20-30% of lacunar infarcts will progress
- Other causes:edema, hydrocephalus, seizures, electrolyte imbalances & infection
- Only small trials; no obvious benefit
Augmentation of Acute Stroke Interventional Procedures

- Experience in PCI of acute MI
  - Often mix anticoagulants, IV antiplatelet drugs
- Little data yet of benefit/safety in acute stroke interventions
Coronary Artery Disease

• More experience with DAPT, ticagrelor & prasugrel

• DAPT advocated for 6-12 months after ACS and longer if high risk (eg multiple prior ACS episodes, diabetes & heart failure) if no increased bleeding risk (age>65, BMI<18.5, prior bleeding, oral anticoagulants)

• Prasugrel better than clopidogrel in ACS but associated with increased bleeding risk and significant risk of stroke in patients with risk of stroke or TIA

• Ticagrelor better than clopidogrel for 1 year but higher rate of bleeding and 10-20% experience non exertion all dyspnea in 1st week; increased risk of bleeding with ASA>100 mg/day vs <100 mg/day

• Several trials support d/c of ASA after 1-3 months of DAPT and continuing clopidogrel or ticagrelor vs DAPT for 1 year (equivalent benefit for recurrent ACS and decreased bleeding risk)

Acute TIA/stroke: Early Treatment (3)

• Cardiogenic embolism
  • Aspirin has modest benefit
  • Anticoagulants offer more robust protection; ? when to initiate

• DVT prophylaxis
  • ASA provides some benefit, but ASA guidelines prefer anticoagulation

• Dissection
  • ASA appears equivalent to heparin for dissection
Case 3

The 55 year old woman with BMI 33 and history of diabetes, hypertension and smoking admitted yesterday morning has improved (NIHSS now 1). Her work up has shown she had a small left internal capsule lacune. She wants to go home. In addition to smoking cessation and medication for her diabetes, hypertension and lipids, she should:

A. Take ASA 81 mg daily
B. Take ASA 325 mg daily
C. Take ASA 81 mg and Clopidogrel 75 mg daily for 21 days then stop one
D. Take ASA 81 mg and Clopidogrel 75 mg daily for 90 days
Acute TIA/Stroke (hospital discharge)

Single vs Dual anti-platelet therapy (ASA vs ASA+clopidogrel)

• 2021 systematic review (Brown DL et al. Stoke 2021;52:e468-e479)

• Based on 3 trials with early initiation (<1 week) and short-term treatment duration (<90 days) DAPT was superior to SAPT for prevention of recurrent ischemic stroke, any recurrent stroke and MACE in people with minor stroke or high risk TIA who were at low risk of bleeding

• Best benefit/risk is in the first 3 weeks

• Future research needed re:
  • Optimal time to start treatment
  • Whether patients with major stroke benefit
  • Whether certain genetic profiles modify the benefit of DAPT treatment
  • Whether agents other than ASA +clopidogrel (esp ASA+Ticagrelor) are better
Case 4

A 74 year old male is new to your practice. He is a former smoker who had a small right hemispheric stroke associated with RICA stenosis 4 months ago for which he underwent a successful CEA. His management should include:

A. ASA 81 mg daily
B. Clopidogrel 75 mg daily
C. ASA 81 mg daily and Clopidogrel 75 mg daily
D. No anti-platelet therapy
Long term Secondary Prevention

Special Subgroup Considerations

• Large vessel
  • Aortic Arch atherosclerosis: antiplatelet treatment (?) Single vs dual) ASA 2021 guidelines
  • Internal Carotid Artery Stenosis (ICAS)
    • Benefit for ASA + Clopidogrel for 30 days but nonsignificant CHANCE trial
    • Risk of recurrence with ICAS extends well beyond 30 days

• Intracranial large vessel disease
  • SAMMPRIS used ASA/Clopidogrel for 90 days followed by ASA alone

• Small vessel disease
  • Single antiplatelet for long term treatment (no data for acute treatment and 20-30% progress)
  • Possible role for cilostazol

• Mixed pathologies: a fib + atherosclerosis
• After a stroke occurs while on ASA
2021 ASA Guidelines for secondary prevention:

• Optimal combination of medications, timing of initiation & duration of DAPT

• Effectiveness & potential harm of DAPT in specific subgroups according to stroke subtype, genetic tests, other factors

• Benefit of switching anti-platelet agent for stroke patients already on 1 agent

• Effectiveness of DOAC’s compared with or in combination with anti-platelet therapy amount noncardioembolic ischemic stroke

• Role of IV anti-platelet therapy to augment acute interventional procedures
THERE ARE LIES, ... DAMN LIES, ... AND STATISTICS.
10% RISK OF STROKE
20% RISK REDUCTION
30% RISK REDUCTION
<p>| | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

20% RISK REDUCTION
• Overall, antiplatelet strategies decrease risk of stroke about 15-15%

• More potent therapies carry higher risks of bleeding

• We need to remember that this is only one of many strategies to help our patients decrease their stroke risk
Stroke Prevention Pyramid

1. Diet and Exercise
2. Quit smoking; drink alcohol in moderation
3. Blood pressure control
4. Cholesterol control
5. Blood sugar control
6. Blood thinners
7. Procedures
Summary

• Platelets play an important role in arterial thrombosis
• Decisions re: treatment depend on benefit/risk (primarily bleeding)
• Antiplatelet therapy is used for arterial thrombosis/emboli
• Anticoagulant therapy is superior for venous thrombosis and A fib
• Bleeding risk is increased in:
  • Age over 65
  • BMI< 18.5
  • Diabetes
  • Prior bleeding
  • Taking oral anticoagulants
• Risk of systemic bleeding can likely be reduced with PPI treatment
• Risk of ICH can likely be reduced with aggressive BP control
Summary (2)

• Antiplatelet therapy IS NOT recommended for primary prevention
• Aspirin (loading dose 180-365 mg/ maintenance 81 mg is recommended for acute stroke therapy)
  • Some evidence suggests better efficacy for 365 mg maintenance if weight >
• Aspirin plus Clopidogrel is recommended for the first 3 weeks after TIA and minor stroke
• Aspirin plus Ticagrelor MAY be an alternate option but bleeding risk is higher
• Long term treatment of large and small vessel disease favors single antiplatelet therapy